13F Data
13F filer · CIK 1750122

Aquilo Capital Management, LLC

SAN FRANCISCO, CA · filing since Q2 2018 · last filing Nov 14, 2018
Reported value
$238.9M
+$117.7M vs prior
Positions
12
New / sold out
1 / 3
Added / reduced
7 / 3
Turnover
8.5%
buys $78.3M · sells $15.3M
Top-10 weight
98.4%

Biggest buys vs Q2 2018

ChangeSecurityShares changeChange %Est. trade value
AddedSPDR SERIES TRUSTPUT+500,000+83.3%+$47.9M
AddedSYNLOGIC INC+691,240+225.3%+$9.8M
NewXENON PHARMACEUTICALS INC+592,802–+$7.8M
AddedFATE THERAPEUTICS INC+404,367+69.7%+$6.6M
AddedSPERO THERAPEUTICS INC+383,000+91.9%+$4.0M
AddedMERUS N V+44,799+3.6%+$884.3K
AddedADURO BIOTECH INC+97,383+4.8%+$715.8K
AddedCYTOMX THERAPEUTICS INC+25,000+3.8%+$462.5K

Biggest sells vs Q2 2018

ChangeSecurityShares changeChange %Est. trade value
Sold outAUTOLUS THERAPEUTICS PLC-150,000-100.0%$-4.0M
ReducedGALAPAGOS NV-34,730-52.6%$-3.9M
Sold outCELLECTIS S A-118,873-100.0%$-3.4M
ReducedLOXO ONCOLOGY INC-17,500-13.8%$-3.0M
Sold outFIVE PRIME THERAPEUTICS INC-64,881-100.0%$-1.0M
ReducedMORPHOSYS AG-913-9.1%$-24.4K

Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.

Reported value by quarter

Q2 2018: $121.3MQ3 2018: $238.9M
Q2 2018Q3 2018

Holdings · Q3 2018

#SecuritySharesValueWeight
1SPDR SERIES TRUSTPUTS&P BIOTECH1,100,000$105.5M44.14%
2MERUS N VCOM1,295,713$25.6M10.70%
3LOXO ONCOLOGY INCCOM109,312$18.7M7.82%
4FATE THERAPEUTICS INCCOM984,596$16.0M6.71%
5ADURO BIOTECH INCCOM2,105,282$15.5M6.48%
6SYNLOGIC INCCOM998,034$14.2M5.94%
7CYTOMX THERAPEUTICS INCCOM674,763$12.5M5.22%
8PIERIS PHARMACEUTICALS INCCOM1,975,098$11.1M4.63%
9SPERO THERAPEUTICS INCCOM799,691$8.4M3.52%
10XENON PHARMACEUTICALS INCCOM592,802$7.8M3.27%
2 more rows. Subscribe for $29/month to see every row, download the data and use the API.